Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

Efficacy and Safety of T+A+RAD in HCC

Phase 2

Conditions: Hepatocellular Carcinoma

Interventions: Radiation: Multifocal Stereotactic Radiotherapy
Drug: Atezolizumab Injection [Tecentriq]
Drug: Bevacizumab

First Posted Date: 2022-05-31

Last Posted Date: 2022-05-31

Lead Sponsor: Fudan University

Target Recruit Count: 42

Registration Number: NCT05396937

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Detection and Analysis of MBC With Heterogeneous ER Expression

Completed

Conditions: Breast Cancer

First Posted Date: 2022-05-26

Last Posted Date: 2024-02-26

Lead Sponsor: Fudan University

Target Recruit Count: 51

Registration Number: NCT05392985

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Real-world Study of UTD1 in Chinese Advanced Breast Cancer

Completed

Conditions: Breast Cancer

First Posted Date: 2022-05-23

Last Posted Date: 2024-02-26

Lead Sponsor: Fudan University

Target Recruit Count: 150

Registration Number: NCT05386511

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Sintilimab and Bevacizumab Biosimilar Combined With PLD in mTNBC

Phase 2

Recruiting

Conditions: Breast Cancer

Interventions: Drug: sintilimab
Drug: bevacizumab biosimilar
Drug: pegylated liposomal doxorubicin

First Posted Date: 2022-05-23

Last Posted Date: 2023-02-16

Lead Sponsor: Fudan University

Target Recruit Count: 41

Registration Number: NCT05386524

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Effect of FMD on Colorectal Cancer Patients

Not Applicable

Recruiting

Conditions: Colorectal Cancer
Fasting Mimicking Diet

Interventions: Other: Fasting mimicking diet

First Posted Date: 2022-05-20

Last Posted Date: 2024-01-05

Lead Sponsor: Fudan University

Target Recruit Count: 602

Registration Number: NCT05384444

Locations: 🇨🇳
Shanghai First People's Hospital,Shanghai Jiaotong University, Shanghai, Shanghai, China
🇨🇳
Shanghai Changhai Hospital, Naval Medical University,, Shanghai, Shanghai, China
🇨🇳
Fudan University,ZhongShan Hospital, Shanghai, Shanghai, China

and more 3 locations

Efficacy of Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Stage IV Ovarian Cancer

Phase 3

Conditions: Ovarian Cancer

Interventions: Drug: Paclitaxel, Carboplatin
Procedure: debulking surgery

First Posted Date: 2022-05-12

Last Posted Date: 2022-05-12

Lead Sponsor: Fudan University

Target Recruit Count: 200

Registration Number: NCT05371301

Locations: 🇨🇳
Fudan university shanghai cancer center, Deparment of gynecologic oncology, Shanghai, Shanghai, China

A Combination Therapy Including Anti-PD-1 Immunotherapy in MSS Rectal Cancer With Resectable Distal Metastasis

Phase 2

Not yet recruiting

Conditions: Advanced Rectal Cancer
Liver Metastasis
Pulmonary Metastasis
Microsatellite Stable Colorectal Carcinoma

Interventions: Combination Product: a combination therapy including tislelizumab

First Posted Date: 2022-05-03

Last Posted Date: 2022-11-14

Lead Sponsor: Fudan University

Target Recruit Count: 52

Registration Number: NCT05359393

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Multimodal Deep Learning Signature for Evaluation of Response to Bevacizumab in Patient With Colorectal Cancer Liver Metastasis

Not yet recruiting

Conditions: Liver Metastases
Colorectal Cancer

Interventions: Drug: Bevacizumab

First Posted Date: 2022-04-29

Last Posted Date: 2023-07-13

Lead Sponsor: Fudan University

Target Recruit Count: 302

Registration Number: NCT05354674

Locations: 🇨🇳
Zhongshan hospital, Shanghai, Shanghai, China

Study on the Correlation Between Immunoglobulin and Liposomal Doxorubicin in Vivo

Phase 2

Conditions: Advanced Malignant Tumors

Interventions: Drug: doxorubicin hydrochloride liposome injection

First Posted Date: 2022-04-29

Last Posted Date: 2022-04-29

Lead Sponsor: Fudan University

Target Recruit Count: 30

Registration Number: NCT05354076

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab

Phase 3

Recruiting

Conditions: HER2-positive Breast Cancer
Metastatic Breast Cancer

Interventions: Drug: Trastuzumab plus chemotherapy
Drug: Trastuzumab in combination with pyrotinib plus chemotherapy

First Posted Date: 2022-04-26

Last Posted Date: 2022-04-26

Lead Sponsor: Fudan University

Target Recruit Count: 240

Registration Number: NCT05346861

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy